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Sanitaria Pere i Virgili (IISPV), Universitat Rovira i Virgili, Reus, Catalonia (Spain).
The flavolignan silibinin was studied for its ability to restore drug sensitivity to EGFR-mutant NSCLC
xenografts with epithelial-to-mesenchymal transition (EMT)-driven resistance to erlotinib. As a single
agent, silibinin significantly decreased the tumor volumes of erlotinib-refractory NSCLC xenografts by
approximately 50%. Furthermore, the complete abrogation of tumor growth was observed with the
co-treatment of erlotinib and silibinin. Silibinin fully reversed the EMT-related high miR-21/low miR-200c
microRNA signature and repressed the mesenchymal markers SNAIL, ZEB, and N-cadherin observed in
erlotinib-refractory tumors. Silibinin was sufficient to fully activate a reciprocal mesenchymal-to-epithelial
transition (MET) in erlotinib-refractory cells and prevent the highly migratogenic phenotype of
erlotinib-resistant NSCLC cells. Given that the various mechanisms of resistance to erlotinib result from
EMT, regardless of the EGFR mutation status, a water-soluble, silibinin-rich milk thistle extract might be a
suitable candidate therapy for upcoming clinical trials aimed at preventing or reversing NSCLC progression
following erlotinib treatment.
T
he discovery of somatic activating mutations in the epidermal growth factor receptor (EGFR) kinase domain
has radically altered the treatment options of patients with non-small cell lung cancer (NSCLC)1–5. For
example, Caucasian patients harboring activating mutations in the EGFR kinase domain, such as a deletion
in exon 19 or L858R, have shown significant responses to the EGFR tyrosine kinase inhibitor (TKI) erlotinib,
including a 70% response rate, 14-month progression-free survival, and 27-month median survival. Accordingly,
the EGFR TKIs erlotinib or gefitinib have become the standard of care for first-line treatment in patients with
advanced NSCLC and whose tumors harbor activating mutations in the kinase domain of EGFR. However,
despite the encouraging clinical findings showing a favorable response to first- and second-line EGFR TKIs,
advanced NSCLC patients with EGFR mutations often respond unpredictably to initial EGFR TKI therapy.
Additionally, patients who initially show dramatic responses invariably relapse due to the development of drug
resistance. Intriguingly, some NSCLC patients with wild-type EGFR also benefit from treatments with EGFR
TKIs. Not surprisingly, numerous research groups are attempting to identify more effective predictive biomarkers
for assessing the response or resistance to EGFR TKIs to optimize therapy for individual patients.
The acquisition of resistance to EGFR TKIs has been attributed to two main mechanisms reviewed in 6–12. The
first is the emergence of malignant clones containing second-site mutations in the EGFR kinase domain that
abrogate the inhibitory activity of EGFR TKIs. The most common lesion is the so-called ‘‘gatekeeper mutation’’,
which involves a substitution of methionine for threonine at position 790 (T790M). The second well-known
mechanism of resistance to gefitinib or erlotinib is the amplification of the MET receptor tyrosine kinase (RTK)
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amplification account for approximately 60–70% of all known causes
of acquired resistance to gefitinib or erlotinib; these amplifications
are not mutually exclusive and can be detected in the same resistant
tumor or may occur independently in different metastatic sites in the
same patient. Consequently, ongoing research has been focused on
identifying the molecular mechanisms accounting for the 30–40% of
EGFR TKI-resistant, EGFR-mutant tumors that do not carry EGFR
mutations or MET amplification13. In this regard, emerging evidence
strongly suggests that the mesenchymal phenotype is closely related
to the lack of responsiveness to EGFR TKIs14–25. First, although
NSCLC cell lines with EGFR-activating mutations are the most sens-
itive to erlotinib, mesenchymal cell lines are highly resistant to erlo-
tinib when compared to epithelial cell lines. Second, the correlation
between an epithelial-to-mesenchymal transition (EMT) signature
and greater resistance to erlotinib can be observed, even in EGFR
wild-type gene cells exhibiting a mesenchymal-like phenotype.
Third, genetic and histological analyses of tumor biopsies from
NSCLC patients with acquired resistance to EGFR inhibitors have
revealed that a subgroup of resistant carcinomas exhibit a pro-
nounced EMT. Fourth, the activation of the receptor tyrosine kinase
AXL, which confers acquired resistance to erlotinib in pre-clinical
models of EGFR-mutated NSCLCs and is overexpressed in approxi-
mately 20% of post-erlotinib-treated patients with EGFR TKI resist-
ance, has been associated with the development of an EMT
phenotype. Fifth, in NSCLC, the EMT phenomenon does not appear
to be a general marker of resistance toward commonly used che-
motherapeutics, such as pemetrexed, docetaxel, and paclitaxel, as
mesenchymal cells appear to be relatively more sensitive to cisplatin,
gemcitabine, and vinorelbine. Sixth, an EMT signature that high-
lights the different patterns of drug responsiveness in epithelial
and mesenchymal NSCLC cells has prognostic value for early-stage
NSCLC and can also predict resistance to EGFR TKIs, regardless of
the EGFR mutation status.
Emerging data have repeatedly implicated EMT in contributing to
both innate and acquired resistance to erlotinib; accordingly, it might
be tempting to suggest that EMT is a core resistance mechanism that
might be targeted to bypass the inhibition of the EGFR pathway in
NSCLC. Indeed, elucidating how EMT could be prevented or
reversed in NSCLC should enable the development of new strategies
aimed at optimizing the efficacy of EGFR TKIs to improve the thera-
peutic outcome of NSCLC patients. Although the inhibition of EMT
can be a critical strategy for delaying or preventing tumor progres-
sion after treatment with EGFR TKIs, the reversal of the EMT-driven
erlotinib-refractory phenotype is urgently needed to expand the cur-
rent EMT-targeted therapies. In this regard, a landmark study
showed that the combination of EGFR TKIs with the lignin silibinin,
the bioactive constituent of silymarin isolated from the dried fruits of
the milk thistle (Silybum marianum) plant26–29, drastically sup-
pressed tumor growth. This was the case for both primary tumors
and the cells that had acquired TKI resistance via the EGFR T790M
mutation30. This finding might open a new, unexpected therapeutic
avenue for the clinical management of EMT-driven, acquired resist-
ance to erlotinib. Silibinin, a potent natural agent, appears to reverse
EMT by decreasing the levels of key EMT transcription factors, such
as SLUG, and increasing the expression levels of E-cadherin31–33.
Because the ability of silibinin to overcome the erlotinib resistance
that is attributed to mechanisms other than second-site EGFR muta-
tions has not been explored and given that the poor water solubility
and low bioavailability of silibinin might severely limit its clinical
efficacy in NSCLC patients, we decided to explore whether a milk
thistle extract rich in silibinin-meglumine, a commercially used
water-soluble form of silibinin complexed with the excipient
amino-sugar meglumine (Fig. 1), can reverse acquired resistance
to EGFR TKIs in animal models. Here, we present the first evidence
that, in the absence of second-site EGFR mutations or the activation
of MET or AXL, a water-soluble formulation of the flavolignan
silibinin, efficiently circumvents EMT-driven resistance to erlotinib
via a mechanism that involves, at least in part, the restoration of the
imbalance of such EMT-related microRNAs as miR-21 and miR-200c
in erlotinib-refractory tumors in vivo.
Results
In the absence of second-site EGFR mutations, erlotinib-refrac-
tory, EGFR-mutant NSCLC mouse xenografts exhibit faster tumor
growth than erlotinib-responsive xenografts. We subcutaneously
implanted parental PC-9 cells and PC-9/Erl-R derivatives34 in
athymic nude mice to compare whether the acquisition of resis-
tance to erlotinib significantly altered the tumor-forming ability of
EGFR-mutant NSCLC cells. In the absence of erlotinib treatment, the
PC-9/Erl-R cells exhibited significantly higher tumorigenicity than
the parental PC-9 cells. The PC-9/Erl-R cells established larger
tumors with shorter latencies in comparison to the parental PC-9
cells (Supplementary Fig. 1). To confirm the genetic changes, which
were previously described in cultured parental and resistant cells in
vitro34, following the acquired resistance to erlotinib in vivo, we
examined genomic DNA directly isolated from frozen tumors. We
assessed the status of 85 possible mutations in the EGFR pathway
using the Human EGFR Pathway qBiomarker Somatic Mutation
PCR array, which combines allele-specific amplification and 59-
hydrolysis probe detection to detect as little as 0.01% somatic
mutations in a background of wild-type genomic DNA. Similarly,
we assessed the erlotinib-sensitizing deletion mutation DE746-A750
in the parental PC-9 cells. However, we failed to detect new co-
occurring mutations in the EGFR gene (including the gatekeeper
EGFR-T790M mutation, in the tumors generated by the PC-9/
Erl-R cells, which maintained the same expression level of EGFR
DE746-A750 as the PC-9 cells (Supplementary Fig. 1). By using
Human EGFR Pathway qBiomarker Somatic Mutation PCR
Arrays, we also confirmed that the PC-9/Erl-R tumors did not
harbor any secondary mutations in the KRAS, NRAS, or BRAF
genes (data not shown).
Oral administration of silibinin delays tumor progression in erlo-
tinib-refractory EGFR-mutant NSCLC mouse xenografts. Silibi-
nin is the primary active constituent of a crude extract (silymarin)
from milk thistle plant (Silybum marianum) seeds. We explored the
ability of an oral milk thistle extract formulation that was enriched
(30% w/w) with a water-soluble form of silibinin complexed with the
amino-sugar meglumine to inhibit the growth of a PC-9/Erl-R
xenograft animal model. When the tumor volumes reached approxi-
mately 100 mm3, as measured with calipers, the mice were randomly
allocated into groups of 6 animals each. The groups received
erlotinib, silibinin, erlotinib and silibinin, or vehicles by oral
gavage. The mice in each group were followed, and their tumors
were measured during the 35 days of treatment; the tumor volume
was calculated for each mouse at each time point. Fig. 2A shows the
rate of tumor growth in the four treatment groups, with the data
plotted as the mean tumor volume in each group over time. In the
erlotinib-treated animals, the tumor volumes were larger than the
initial volume at all time points, and this increase became statistically
significant at day 14. When compared to the animals in the vehicle-
treated group (mean tumor volumes of 965 6 155 mm3), 5 weeks of
treatment with erlotinib for 5 days/week at 100 mg/kg body weight
by oral gavage failed to prevent tumor growth in animals xenografted
with PC-9/Erl-R cells, showing a mean tumor volume was as high as
767 6 180 mm3. However, 5 weeks of treatment with silibinin for
5 days/week at 100 mg/kg body weight by oral gavage caused a
marked time-dependent reduction in xenograft growth. Thus,
compared to the mean xenograft tumor volume in both the
untreated control and erlotinib-treated animals, the mean tumor
volume of the silibinin-treated mice was significantly smaller (460
6 120 mm3). Throughout the duration of the experiment, the mice
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treated with silibinin did not show any gross signs of toxicity or
possible adverse effects, as assessed by body weight gain and diet
consumption profiles (data not shown). Taken together, these
results demonstrate the in vivo antitumor efficacy of oral silibinin
administration on erlotinib-refractory, EGFR-mutant tumor xeno-
grafts, without any apparent signs of toxicity.
Systemic silibinin administration sensitizes erlotinib-resistant
xenografts to erlotinib. Daily oral gavage of the mice with
erlotinib-treated xenografts with silibinin resulted in a dramatic
reduction in the mean tumor volume to 143 6 60 mm3. Although
erlotinib treatment only reduced the tumor volume of the PC-9/Erl-
R xenografts by 20% at 35 days post-treatment, the combined
treatment of erlotinib and silibinin reduced the tumor volume of
the PC-9/Erl-R xenografts by an impressive 85% over the same
treatment period. Thus, although the tumors increased to 7 times
their initial volume in the group treated with erlotinib, there were no
statistically significant changes in tumor size over the same time
period in the erlotinib and silibinin-treated mice. These findings
strongly suggest that the erlotinib-refractory PC-9/Erl-R xenografts
were sensitized to the tumor growth inhibitory effects of erlotinib in
the presence of silibinin. This was reflected by the percentage of
tumor growth inhibition, which was calculated as 1-treated/control
volume ratios (1-T/C) (Fig. 2B). The inhibitory effect of erlotinib was
modest, reaching a maximum after 4 weeks (26%) and decreasing
toward the end of the treatment to the very low levels of activity
achieved during the first weeks of treatment (10%–20%).
Conversely, after 2 weeks of treatment, the anti-tumor activity of
the single agent silibinin was equivalent to the highest inhibitory
effect (24%) of erlotinib, which was achieved after 4 weeks of
treatment. The anti-tumor effect of silibinin reached a maximum
after 4 weeks (52%) and remained constant until the end of the 5-
week treatment schedule (52%). Of note, the anti-tumor activity in
the combined erlotinib and silibinin group (57%) was already greater
Figure 1 | HPLC chromatogram of milk thistle extract with 30% (w/w) of water-soluble silibinin meglumine at 288 nm. Compounds are identified
by number as follows: silychristin A (1), silydianin (2), silychristin B (3), silybin A (4), silybin B (5), isosilybin A (6) and isosilybin B (7). Chemical
structures of the compounds are also shown.
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after only 7 days of treatment than the maximum activity achieved at
any time with the single-agent treatment. Moreover, the inhibitory
effect of the combination increased in a time-dependent manner,
reaching a maximum of 85% after 35 days.
Oral silibinin reduces the expression of EMT-related markers in
erlotinib-refractory tumors in vivo. MicroRNAs (miRNAs) are
single-stranded, 19 to 25-nucleotide-long, short RNAs that elicit
regulatory effects on the post-transcriptional regulation of genes by
binding to the 39 untranslated region (39UTR) of a target messenger
RNA (mRNA), leading to translational repression or target mRNA
cleavage. It is well established that miRNAs regulate EMT through
the regulation of E-cadherin and other molecules, such as the
transcription factor ZEB35–40. Additionally, recent studies have
suggested that natural agents, including the polyphenols curcumin,
(-)-epigallocatechin-3-gallate, and resveratrol, can alter miRNA
expression profiles, leading to the reversal of EMT and enhancing
the efficacy of conventional cancer therapeutics41–50. As such, we
hypothesized that the plant polyphenol silibinin may also function
as a previously unrecognized regulator of miRNAs that might lead to
the reversal of the EMT phenotype. After 35 days of oral treatment
with silibinin, tumors were collected and snap frozen for the isolation
of total RNA. We then used a customized array for the quantitative,
real-time PCR (qRT-PCR) analysis of 12 miRNAs that are func-
tionally associated with EMT and the reciprocal mesenchymal-
to-epithelial transition (MET), namely miR-31, miR-21, miR-10b,
miR-103, miR-9, let-7a, miR-200a, miR-205, miR-200c, miR-141,
miR-155, and miR-429. Using a cutoff of a 4-fold or greater
difference to determine significant regulatory effects on miRNA
expression levels, we found that the expression of EMT-driving
miR-2151–56 was drastically augmented in the PC-9/Erl-R-derived
tumor tissues (15 6 3-fold up-regulation; Fig. 3). miR-31, another
oncogenic miRNA that is closely related to the pro-EMT effects of
miR-2151,57–59, was also found to be significantly overexpressed in the
PC-9/Erl-R-derived tumor tissues (5.7 6 1-fold up-regulation;
Fig. 3). Conversely, miR-200c, a member of the miR-200 family
and a key regulator of EMT that controls the transition between
non-stem cell-like and cancer stem cell (CSC)-like cellular states
and that has been shown to determine the response to EGFR
TKIs37,41,60–64, was found to be significantly underexpressed in the
PC-9/Erl-R-derived tumor tissues (23.4 6 1-fold down-
regulation; Fig. 3). Remarkably, the PC-9/Erl-R tumor samples
treated with oral silibinin exhibited a full reversion of the
respective up- or down-regulation of miR-21, miR-31, and miR-
200c that was observed in the erlotinib-refractory PC-9/Erl-R
tumors. Thus, the systemic administration of silibinin was able to
restore the altered expression pattern of EMT-related miRNAs,
returning them to the control levels observed in the erlotinib-
responsive PC-9 parental tumors (Fig. 3).
Recent studies have revealed that miR-21 expression confers
tumor aggressiveness and metastatic potential, at least in part, by
inducing the expression of and cooperating with the EMT master
regulatory gene, SNAIL155. Accordingly, we used qRT-PCR to
explore whether the ability of silibinin to down-regulate miR-21
expression affected the expression of SNAIL1. We confirmed that
SNAIL1 expression was markedly reduced in the tumor tissues har-
vested from the erlotinib-refractory PC-9/Erl-R xenografts and that
silibinin treatment restored SNAIL1 expression to the basal levels
observed in the erlotinib-responsive PC-9-formed xenograft tissues
(Fig. 3). Because all the studies published to date have described the
epithelial transcriptional repressors ZEB1 and ZEB2 as critical targets
of miR-200 family members, we examined whether the ability of
silibinin to promote the re-expression of miR-200c significantly
impacted the expression of its predicted targets, ZEB1/2. qRT-PCR
analyses confirmed that the ZEB1 gene was significantly up-regu-
lated in the erlotinib-refractory PC-9/Erl-R xenograft tissues (Fig. 3).
In contrast, oral treatment with silibinin down-regulated ZEB1 gene
expression to the basal levels observed in the erlotinib-responsive
PC-9 xenograft tissues. These results suggested that the antagonism
of miR-21 and re-expression of miR-200c induced by silibinin
decreased the mRNA expression of mesenchymal phenotype cell
Figure 2 | Oral treatment of erlotinib-refractory, EGFR-mutant NSCLC
xenograft-bearing animals with silibinin: Impact on the efficacy of the
EGFR TKI erlotinib in vivo. (A). Shown are the mean tumor volumes
(6SD) in PC-9/Erl-R xenograft-bearing nude mice following oral gavage
with erlotinib, silibinin or erlotinib plus silibinin for five weeks. Data
represent means 6 SD. *P , 0.05 (Student’s t-test), **P , 0.005
(Student’s t-test), and n.s. non-statistically significant results (Student’s t-
test), versus erlotinib-treated mice. (B). Antitumor activity was calculated
for individual tumors as the percentage of tumor growth inhibition,
according to the following formula: 100 2 [(Vx/Vc) 3 100], where Vx is the
tumor volume for treated mice and Vc is the tumor volume in the control
group at a given x time.
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biomarkers. We also studied the relative mRNA expression of N-
cadherin (CDH2), a mesenchymal cadherin associated with EMT
that has consistently been found to be up-regulated in most biopsies
obtained from recurrent NSCLC patients showing signs of EMT in
response to the induction of erlotinib resistance65. In accordance with
our other findings, we found that N-cadherin was significantly
decreased in the PC-9/Erl-Rd xenograft tissues following treatment
with silibinin.
Silibinin reverses the mesenchymal phenotype of erlotinib-refrac-
tory PC-9/Erl-R cells in vitro. To confirm that the effects observed
with regard to EMT-related erlotinib efficacy in the mice treated with
oral silibinin were also due to the direct effect of silibinin on the
tumor cells, and not only on the mouse tissue micro-environment,
we evaluated whether silibinin alone was sufficient to reactivate an
epithelial phenotype in erlotinib-refractory PC-9/Erl-R mesench-
ymal cells in vitro. Microscopically, the PC-9/Erl-R cells exhibited
a spindle cell-like morphology that was notably different from the
parental PC-9 cells. As expected, the erlotinib-refractory PC-9/Erl-R
cells displayed EMT features, including the reorganization of
filamentous actin (F-actin), with a significant enhancement of
stress fibers, a decrease in the abundance of the epithelial cell-cell
adhesion protein, E-cadherin, and an increase in the abundance of
the mesenchymal adhesion protein vimentin when compared to the
erlotinib-responsive PC-9 parental epithelial cells (Figs. 4 and 5). Of
note, treatment with silibinin-meglumine induced the re-expression
of E-cadherin, which correlated with morphological changes
consistent with the erlotinib-refractory PC-9/Erl-R cells under-
going the reciprocal mesenchymal-to-epithelial transition (MET).
Analyses of the actin stress fibers and vimentin expression before
and after treatment with silibinin-meglumine revealed that the PC-9/
Erl-R cells had reverted from the erlotinib-refractory, acquired
mesenchymal state to the original, erlotinib-sensitive, de novo
epithelial cellular state (Figs. 4 and 5). Importantly, all these
phenomena related to changes in the cell migratory behavior of
PC-9/Erl-R cells. In vitro scratch wound healing assays showed
that the highly migratogenic phenotype of PC-9/Erl-R cells was
largely prevented in the presence of silibinin; thus, silibinin-treated
PC-9/Erl-R cells demonstrated a significantly slower cell migration
speed compared to the basal locomotory activity of untreated PC-9/
ErlR cells (Fig. 5).
Discussion
By culturing erlotinib-hypersensitive PC-9 cells harboring the erlo-
tinib-sensitizing EGFR exon 19 mutation DE746-A750 in the pres-
ence of high concentrations of erlotinib over a period of several
months, we were able to isolate PC-9 derivatives capable of growing
at erlotinib concentrations of up to 10 mmol/L34. We recently
described that, in the absence of second-site EGFR mutations,
alternative activation of MET, AXL, or HER2, gain of secondary
mutations in the KRAS, NRAS, or BRAF genes, and loss of the mutant
delE746-A750 EGFR gene itself66, acquired resistance to erlotinib is
mostly correlated with a significant enrichment in EMT features34.
By taking advantage of this unique model of non-mutational, EMT-
driven acquired resistance to erlotinib, we explored whether an oral
formulation of a milk thistle extract enriched (30% w/w) with a
water-soluble derivative of the bioactive lignan silibinin (i.e., silibinin
complexed with the excipient amino-sugar meglumine) was able to
circumvent erlotinib resistance in EGFR-mutant PC-9/Erl-R xeno-
grafts. This paper reports, for the first time, the inhibitory effect of
silibinin on NSCLC cancer growth in an in vivo xenograft model of
EMT-driven acquired resistance to erlotinib that was generated by
the subcutaneous injection of PC-9/Erl-R cells in athymic mice.
Specifically, we demonstrated that 5 weeks of oral administration
of 100 mg/kg per day silibinin was sufficient to significantly inhibit
the growth of PC-9/Erl-R tumor xenografts, Importantly, our data
demonstrate that silibinin can reverse the resistance to erlotinib
because mice concurrently exposed to silibinin and erlotinib show
an impressive 85% reduction in tumor growth after 35 days of com-
bined treatment. No evidence of tumor regrowth was noted in the
combination group, even after discontinuation of the drugs for two
weeks. Although these findings suggest that the biological activity of
silibinin might continue after administration has ceased, long-term
monitoring of tumor growth and spread in the mice should be per-
formed before unambiguously concluding that silibinin improves
recurrence free survival in our erlotinib-refractory xenograft models.
Figure 3 | Oral treatment with silibinin reverses the EMT-related high miR-21/low miR200c microRNA signature and downregulates mesenchymal
markers in erlotinib-refractory EGFR-mutant NSCLC xenograft-bearing animals. Figure shows the difference (fold-change mean values 6 SD versus
untreated PC-9 parental cells; n 5 4) in the three differentially expressed miRNAs (i.e., miR-21, miR-31, and miR-200c) between erlotinib-resistant PC-9/
Erl-R tumor samples and erlotinib-responsive PC-9 tumor samples following oral treatment with silibinin for five weeks (left panel). Figure also
shows the effects of oral treatment with silibinin in the expression of the mesenchymal markers SNAIL1, ZEB1, ZEB2, and N-cadherin (fold-change mean
values 6 SD versus untreated PC-9 parental cells; n 5 4), which were found significantly overrepresented in erlotinib-refractory EGFR-mutant NSCLC
xenografts (right panel).
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The process of EMT is regulated by the expression status of spe-
cific miRNAs during tumor development and disease progression;
miR-21 is one such miRNA that is overexpressed in solid tumors
compared to paired benign and normal tissues. Indeed, miR-21 is
considered to be an oncogenic miRNA that exhibits anti-apoptotic
activity in various types of cancer cells and appears to control the
EMT process and the CSC phenotype by targeting PTEN or collab-
orating with the EMT transcription factor SNAIL51–56. This suggests
Figure 4 | Silibinin enhances the epithelial phenotype in PC-9 parental cells and reverses the mesenchymal phenotype in PC-9/Erl-R cells (I). PC-9
parental cells and erlotinib-resistant PC-9/Erl-R cells were cultured for 3 days in the absence or presence of 100 mg/mL of silibinin-meglumine. Top panels.
After fixation and permeabilization, the subcellular distribution of F-actin, the epithelial marker E-cadherin, and of the mesenchymal-specific
marker vimentin was assessed after staining with anti-F-actin, anti-E-cadherin, and anti-vimentin antibodies and Hoechst 33258 for nuclear
counterstaining, as specified. Images show representative portions of the untreated- and silibinin meglumine-treated cells in montages of 4 3 4, which
were captured in different channels for F-actin (red), E-cadherin (green), vimentin (green), and Hoechst 33258 (blue) with a 203 objective. Images were
merged on a BD Pathway 855 Bioimager System with BD Attovision software.
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that the antagonism of miR-21 could be therapeutically beneficial for
the treatment of drug-refractory tumors that are driven by EMT-like
phenomena. The miR-200 family is another example of a group of
miRNAs associated with cancer recurrence and overall survival that
plays an important role in the regulation of EMT. The low expression
of members of the miR-200 family plays an important role in cancer
metastasis by controlling the EMT process and EMT-driven resist-
ance to cancer therapies37,41,60–64,67–69. The reactivation of miR-200 by
novel approaches may serve as an inhibitor of EMT, which may
either reverse or eliminate the EMT phenotype, enabling anti-cancer
drugs, such as EGFR-directed therapy, to effectively circumvent
EMT-associated drug resistance. In this study, we first compared
the expression of EMT-related miRNAs between erlotinib-sensitive
and erlotinib-refractory NSCLC tumor tissues and investigated
whether the natural agent silibinin could function as a novel
microRNA-modulating anticancer agent. We found that the express-
ion levels of miR-21 and miR-200c were significantly up-regulated
and down-regulated, respectively, in the erlotinib-refractory tumors.
Accordingly, these tumors showed EMT characteristics, including a
high expression of such mesenchymal markers as SNAIL, ZEB, and
N-cadherin. Interestingly, we also documented that the increased
expression of miR-21 and attenuated expression of miR-200c, a sig-
nature of tumor aggressiveness, in the erlotinib-resistant tumors was
significantly affected by treatment with silibinin. Indeed, silibinin
treatment down-regulated miR-21 and up-regulated miR-200c,
and, consequently, the reversion of the high miR-21/low miR-200c
signature resulted in the down-regulation of SLUG, ZEB1, and N-
cadherin, a result that was consistent with the reversal of the EMT
phenotype. We also showed that the combination of silibinin with
erlotinib was much more effective than either agent alone, suggesting
that the alterations in specific miRNAs mediated by silibinin, which
led to the reversal of the mesenchymal phenotype, could be a novel
approach for the prevention of erlotinib resistance in NSCLC treat-
ment. Nevertheless, it is reasonable to suggest that silibinin should be
added to the current list of microRNA-modulating anticancer agents
that can efficiently target the EMT phenotype.
Our results should prompt further interest in the use of silibinin as
a drug modality, as they raise the possibility that the EMT arising
during erlotinib-resistance development, as observed in EGFR-
mutant NSCLC, can be countered by the silibinin combination.
This can be readily tested in a clinical setting; indeed, there has been
an effort to translate the relevance of preclinical anticancer efficacy
studies into the clinical setting, specifically with regard to determin-
ing the comparable doses required for humans. In this respect, the
calculation of the human equivalent dose (HED) using normalization
of the body surface area rather than weight has been advocated70. On
the basis of the formula proposed for calculating HED, animal dose
(mg/kg) x (animal Km factor/human Km factor), we found that the
corresponding HED for the maximum dose of silibinin used in our in
vivo study, which was equivalent to 100 mg/kg mouse body weight, is
a human equivalent dose of 8.11 mg/kg. This equates to a 486.49-mg
dose of silibinin for a 60-kg individual, an HED that is likely within
the dose that can be achieved in target cancer tissues. When colorectal
cancer patients were given 1.45 g/day of silipide, a formulation of
silibinin with better bioavailability, for 7 days, this dosage was found
to be safe and achieved levels of up to 4 mmol/L in the plasma,
2.5 nmol/g tissue in the liver, and 141 nmol/g in the colorectal tis-
sue71. Thus, the effective doses of silibinin used in the present in vivo
study are within the range of physiologically achievable concentra-
tions of silibinin found in the tissues of cancer patients given similar
doses of silibinin. Moreover, it is known that silibinin has poor water
solubility. However, the ionization ability of silibinin increases when
it is combined with meglumine, and silibinin-meglumine has a high
water solubility. Our development of a water-soluble formulation of
silibinin is crucial for target preparations, as it will enable new for-
mulation breakthroughs for silibinin-meglumine-containing injec-
tions, granules, or beverages. In addition, one of the principles of
combination therapy is that the side effects of the two drugs should
not overlap. Considering the relatively non-toxic nature of such nat-
ural agents as silibinin, which has been widely used for many years
with negligible toxicity, better treatment outcomes may be achieved
through the novel and safe approach of targeting EMT-type,
Figure 5 | Silibinin promotes mesenchymal to epithelial conversion of
erlotinib-resistant PC-9/Erl-R cells. Top panels. Erlotinib-resistant PC-9/
Erl-R cells were cultured for 3 days in the absence or presence of 100 mg/mL
of silibinin. Top panels. After fixation and permeabilization, the subcellular
distribution of F-actin, the epithelial marker E-cadherin, and of the
mesenchymal-specific marker vimentin was assessed after staining with
anti-F-actin, anti-E-cadherin, and anti-vimentin antibodies and Hoechst
33258 for nuclear counterstaining, as specified. Images show representative
portions of the untreated- and silibinin meglumine-treated cells, which
were captured in different channels for F-actin (red), E-cadherin (green),
vimentin (green), and Hoechst 33258 (blue) with a 203 objective. Images
were merged on a BD Pathway 855 Bioimager System with BD Attovision
software. Bottom panels. Figure shows representative microphotographs of
wound healing assays 0, 24, and 48 h after incisions of confluent PC-9/ErL-
R cells cultured in the absence or presence of silibinin (100 mg/mL).
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erlotinib-refractory NSCLC cells with silibinin-meglumine combined
with EGFR TKIs (such as erlotinib). A highly efficacious, long-term
drug-release delivery system for silibinin-meglumine that must be
safe after oral or intravenous administration needs to be developed.
The pre-clinical findings of the present study, along with the lack of
any apparent toxicity associated with silibinin, underscore the effi-
cacy of silibinin against erlotinib-refractory, EGFR-mutant NSCLC,
with translational potential in the immediate future.
Because mesenchymal-type NSCLC cancer cells are more resistant
to EGFR TKIs than epithelial-type NSCLC cancer cells, regardless of
the EGFR mutation status, and given that various erlotinib-resistance
mechanisms occur via the induction of EMT, the discovery of phar-
macological approaches that are able to reverse the tumor status of
EMT features could identify new strategies for sensitizing this
important subgroup of EGFR TKI-resistant NSCLC tumors. The
results presented in this article showed, for the first time, that the
nontoxic, natural agent silibinin can effectively reverse EMT.
Specifically, silibinin activates the MET genetic program in EGFR-
mutant NSCLC cells that have acquired resistance to erlotinib.
Mechanistically, this phenotype is associated with the EMT-related
high miR-21/low miR-200c microRNA signature (Fig. 6). We also
found that silibinin down-regulates the expression of miR-21 and
promotes the re-expression of miR-200c in erlotinib-refractory
tumors, providing a molecular mechanism for the observed reversal
of EMT to MET, along with the complete reversal of erlotinib res-
istance in vivo. These novel findings suggest that the anticancer
activity of the bioactive lignan silibinin against aggressive NSCLC
tumors is, in part, due to the reversal of the EMT phenotype. The
administration of a water-soluble, silibinin-rich milk thistle extract
should be tested in upcoming clinical trials to assess whether it can
prevent or reverse EMT-driven NSCLC progression following erlo-
tinib treatment.
Methods
Drugs and chemicals. The water-soluble milk thistle extract was provided by
Monteloeder, S. L. in its silibinin-meglumine salt form (Elche, Alicante, Spain). The
milk thistle extract composition was analyzed and quantified by HPLC–145 DAD-
ESI-MS/MS on an Agilent LC 1100 series (Agilent Technologies, Inc., Palo Alto, CA,
USA). The retention time, UV spectra, and MS/MS data of the sample peaks were
compared to data reported in the literature72–74. Quantitation of the main
flavonolignan compounds was performed using ChemStation for LC 3D software
(Agilent Technologies Life Sciences and Chemical Analysis, Waldbronn, Germany),
and the silibinin equivalents were determined with silibinin standards (Sigma–
Aldrich). The EGFR (HER1) TKI erlotinib (TarcevaH) was a kind gift from Roche
Pharmaceuticals. Stock solutions of erlotinib at 10 mmol/L were prepared in DMSO,
and aliquots were stored in the dark at 220uC until use. For the experiments, all drug
solutions were prepared fresh from stock solutions and were diluted with the cell
growth medium. The control cells were cultured in media containing identical
concentrations (v/v) of vehicle.
Generation of PC-9 cells with acquired resistance to erlotinib. PC-9 NSCLC-
derived cells expressing the EGFR exon 19 deletion mutation (delE746-A750) were
obtained from the IBL cell bank (Gunma, Japan). PC-9 cells with acquired resistance
to erlotinib were generated as previously described34.
Tumor cell implantation experiments. A total of 40 female athymic nude mice (four
to five weeks old, 23 to 25 g) purchased from Harlam Laboratories (France) were
subcutaneously inoculated with 5 3 106/100 ml PC-9/Erl-R cells. Two independent
experiments were performed, and the data obtained from the two experiments were
pooled. Subcutaneous tumor growth was monitored daily; when the solid tumors
reached a volume of 100 mm3, the animals were randomly assigned to groups of 6
animals each. These groups were treated with vehicle control, erlotinib (100 mg/kg, 5
days a week), silibinin-meglumine (100 mg/kg, 5 days a week), or erlotinib plus
silibinin-meglumine. All the drugs were administered via oral gavage. The mice were
weighed once per week after dosing, the tumor sizes were measured daily with
electronic calipers, and the tumor volumes were calculated with the following
formula: volume (mm3) 5 length 3 width2 3 0.5. The experiments were approved by
the Institutional Animal Care and Use Committee (IACUC) of the Institut
d’Investigació Biomèdica de Bellvitge (IDIBELL; Animal Use Protocol #6302
authorized by the Animal Experimental Commission of the Catalan Government,
Barcelona, Spain). After 35 days of oral treatment, the mice were killed by cervical
dislocation, and the tumors were collected. The tumor samples were divided for DNA,
microRNA, and mRNA analyses.
Quantitative real-time polymerase chain reaction (qRT-PCR). For the purification
of microRNA and total RNA from the tumor tissues, we used Qiagen miRNeasy Mini
kits (Cat. No. 217004) and QIAshredder columns, according to the manufacturer’s
instructions. To complete the miRNA PCR assay procedure, we reverse transcribed
our small RNA samples into first-strand cDNA, the template for PCR, using the RT2
miRNA First Strand Kit (Cat. No. MA-03/331401; SABiosciences). Real-time PCR-
based miRNA expression profiling was performed with a customized miRNA PCR
array in a 96-well format, as described in the SABiosciences RT miRNA qPCR Assays
manual. One microgram of total RNA was reverse-transcribed to cDNA using the
Reaction ReadyTM First Strand cDNA Synthesis Kit (SABiosciences) and applied to a
customized PCR array in a 96-well format. The PCR array contained the following
panel of genes: GSC, KRT14, KRT19, NUMB, TCF3, TCF4, SDC1, ZO-1, CD44,
TWIST, SNAI1, VIM, SLUG, CDH1, ZEB1, CDH2, ZEB2, FN1, and CD24. The arrays
were processed according to the SABiosciences RT-PCR manual and analyzed using
an Applied Biosystems 7500 Fast Real-Time PCR System with an automated baseline
and threshold cycle detection. The data were interpreted using a web-based PCR array
analysis tool from SABiosciences.
Immunofluorescence staining and high-content confocal imaging. For imaging,
the cells were seeded at a density of approximately 5,000 cells/well in 96-well clear-
bottom tissue culture plates (Becton Dickinson Biosciences; San Jose, CA) optimized
for automated imaging applications. TritonH X-100 permeabilization and blocking,
primary antibody staining, secondary antibody staining using Alexa FluorH 488/594
goat anti-rabbit/mouse IgGs (Invitrogen-Molecular Probes, Eugene, Oregon), and
counterstaining (using Hoechst 33258; Invitrogen) were performed according to
protocols from BD Biosciences. The images were captured in different channels for
Alexa FluorH 488 (pseudocolored green), Alexa FluorH 594 (pseudocolored red), and
Hoechst 33258 (pseudocolored blue) using a BD PathwayTM 855 Bioimager System
(Becton Dickinson Biosciences, San Jose, California) with 203 or 403 objectives (NA
075 Olympus). Merged images were obtained according to the recommended Assay
Procedure using the BD AttovisionTM software.
Wound-healing motility assays. PC-9/Erl-R cells were seeded onto six-well dishes at
1 3 105 per well. A single scratch wound was creased using a p10 micropipette tip into
confluent cells. Cells were washed twice with PBS to remove cell debris, supplemented
with regular growth medium in the absence or presence of silibinin, and monitored.
Images were captured by phase-contrast microscopy at 0, 24, and 48 h after
wounding.
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Fundación Cientı́fica de la Asociación Española Contra el Cáncer (AECC, Spain), and the
Ministerio de Ciencia e Innovación (SAF2009-11579 and SAF2012-389134, Plan Nacional
de I 1 D 1 I, MICINN, Spain). Alejandro Vazquez-Martin received a Sara Borrell
post-doctoral contract (CD08/00283) from the Ministerio de Sanidad y Consumo, Fondo
de Investigación Sanitaria -FIS-, Spain). Sı́lvia Cufı́ received a research fellowship
(BES-2010-032066, Formación de Personal Investigador, FPI) from the Ministerio de
Ciencia e Innovación (MICINN, Spain). This work was also supported by grants
AGL2011-29857-C03-03 (MICINN, Spain), PROMETEO/2012/007 and ACOMP/2013/
093 (Generalitat Valenciana), and CIBER (CB12/03/30038, Fisiopatologı́a de la Obesidad y
la Nutrición, CIBERobn, Instituto de Salud Carlos III).
Author contributions
J.A.M., J.B.-B., A.S.-C., J.J., V.M. and A.V.M. designed the study. S.C., C.O.F., A.V.M.,
V.Z.T.-G., J.J., E.C., B.C.F., R.B., A.S.-C., E.B.-C. and E.C. performed the experiments.
J.A.M., V.M., B.M.C., J.B.-B., J.J. and J.V. analysed the data. J.A.M. wrote the paper.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: AstraZeneca (Spain) provided partial financial support for
the present study via an educational grant to Dr. Javier A. Menendez and Dr. Joaquim
Bosch-Barrera.
How to cite this article: Cufı́, S. et al. Silibinin suppresses EMT-driven erlotinib resistance
by reversing the high miR-21/low miR-200c signature in vivo. Sci. Rep. 3, 2459;
DOI:10.1038/srep02459 (2013).
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2459 | DOI: 10.1038/srep02459 10
